Dr. Tawbi on the Safety Profile of Relatlimab Plus Nivolumab in Advanced Melanoma
Source: OncLive, July 2021
Hussein A. Tawbi, MD, PhD, deputy chair, professor, director of melanoma clinical research and early drug development, director of personalized cancer therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of relatlimab plus nivolumab (Opdivo) in advanced melanoma.
